Clinical Trials Logo

Pruritus clinical trials

View clinical trials related to Pruritus.

Filter by:

NCT ID: NCT06297499 Not yet recruiting - Clinical trials for Pruritus Caused by Drug

Ondansetron Use for Preventing Pruritus In Patients Undergoing Cesarean Section

Start date: March 2024
Phase: Phase 1
Study type: Interventional

Opioids are often added with a local anesthetic to enhance the duration and quality of spinal anesthesia for cesarean delivery patients. However, spinal opioids are associated with a wide variety of side effects such as nausea, vomiting, (N/V) and pruritus (itching). The occurrence of pruritus can vary between 30% and 100% making pruritus the most common side-effect of intrathecal opioids and this rate is even higher in pregnant patients. Pruritus may require treatment which can be ineffective or sometimes reverse the analgesic effect of the opioids. Ondansetron is a safe and very commonly used Serotonin receptor antagonist treatment for local anesthetic opioid-induced pruritus used in pregnancy. The effect of different administration times of ondansetron in reducing pruritus or N/V in cesarean section (CS) cases has not been extensively studied and thus, this prospective study can help guide future clinical management of side effects caused by spinal intrathecal morphine administration.

NCT ID: NCT06290375 Not yet recruiting - Pruritus Clinical Trials

A Study of HSK21542 in a Peritoneal Dialysis Pruritus Population.

Start date: March 8, 2024
Phase: Phase 2
Study type: Interventional

This is a two- stage study. Stage I is a multicenter, open-label trial;Stage II was a multi-center, randomized, double-blind, placebo-controlled trial. About 250 maintenance peritoneal dialysis patients with moderate or above pruritus are planned to be enrolled.

NCT ID: NCT06262607 Recruiting - Clinical trials for Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP)

A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica

Start date: January 29, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase 2, randomized, double-blind, vehicle-controlled study to assess the efficacy and safety of CLE-400 topical gel for the treatment of chronic pruritus in adult subjects with Notalgia Paresthetica (NP).

NCT ID: NCT06243120 Not yet recruiting - Clinical trials for Pruritus Caused by Drug

Intravenous Lidocaine for Treating Intrathecal Fentanyl Induced Pruritus

Start date: March 1, 2024
Phase: Early Phase 1
Study type: Interventional

The study will assess efficacy of intravenous lidocaine 1 mg/kg diluted with 0.9% sodium chloride to a volume of 100 ml to suppress intrathecal fentanyl induced pruritus. This will be compared to control group who will receive 100 ml normal saline as placebo. The main outcome is regression of initial VAS score with incidence of pruritus.

NCT ID: NCT06226610 Not yet recruiting - Pruritis Clinical Trials

Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

The goal of this study is to test the efficacy of Dupixent in improving post-burn itching symptoms versus the current standard of care.

NCT ID: NCT06225323 Recruiting - Cesarean Section Clinical Trials

Effect of Lidocaine Infusion on Neuraxial Opioid-induced Pruritus After Cesarean Section

Start date: January 29, 2024
Phase: N/A
Study type: Interventional

The aim of this study is to assess the efficacy and potency of lidocaine infusion as a preventive measure on pruritus response after injection of 200 micro gram morphine with bupivacaine subarachnoid block, spinal anesthesia, in cesarean section.

NCT ID: NCT06190132 Completed - Clinical trials for Uremic Pruritus in Hemodialysis Patients

The Effect of Omega-3 Fatty Acids Versus Gabapentin in Uremic Pruritus in Hemodialysis Patients

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

omega-3 fatty acids versus gabapentin in uremic pruritus in hemodialysis patients.

NCT ID: NCT06188546 Not yet recruiting - Clinical trials for Pruritus Caused by Drug

Propofol for Prophylaxis of Morphine Induced Pruritis in Caesarean Section

Start date: January 1, 2024
Phase: Phase 3
Study type: Interventional

the goal of this randomized clinical trial is to find the optimum sub hypnotic dose of iv propofol that prevents the incidence of itching induced from intrathecal morphine used in spinal anesthesia in caesarean section operation. the main questions it aim to answer are the number of patients complained of pruritus in the first 24 hours post operative period and the severity of the pruritus. participants will be divided into 4 groups. 1st group receives 0 mg of propofol , 2nd receives 10 mg , 3rd receives 20 mg and the 4th receives 30 mg.

NCT ID: NCT06159686 Completed - Uremic Pruritus Clinical Trials

The Efficacy of Hemp-containing Cream Versus Placebo in the Treatment of Uremic Pruritus

Start date: September 15, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Uremic pruritus is a significant burden on hemodialysis patients, affecting approximately 46% of individuals undergoing dialysis. Various mechanisms, including inadequate dialysis, increased uremic toxins, inflammatory cytokines, parathyroid hormone, phosphorus, dry skin, mast cell histamine secretion, and nerve stimulation through μ-opioid receptors and nociceptors, contribute to uremic pruritus. Current treatments include antihistamines, gabapentin, moisturizer creams, and capsaicin creams, with limited success, as only 10% of patients find relief. Cannabinoids were also mentioned in uremic pruritus treatment but are less commonly used and there are no randomised controlled trial. Cannabinoid binding to CB1 and CB2 receptors inhibits mast cell differentiation, aggregation, and histamine release, whereas cannabinoid binding to TRP-iron receptors reduces peripheral nerve activation. Thus, cannabinoid seem to effective in relieving pruritus via various mechanisms. This study aims to assess the effectiveness of a hemp-containing cream in comparison to a placebo for treating uremic pruritus among hemodialysis patients.

NCT ID: NCT06120907 Recruiting - Pruritus Clinical Trials

Swiss Itch Registry

SWITCHR
Start date: October 18, 2023
Phase:
Study type: Observational [Patient Registry]

This project is to develop a national registry for CP patients. Patients admitted to this registry will be examined and documented with PROs, physician-based assessments, blood tests, 3D photodocumentation and, if indicated, by skin biopsies, neurophysiological testing and radiological imaging at defined timepoints. The data collection will allow deepened insights into patient needs, different mechanisms and courses of pruritic conditions, treatment outcomes and treatment-related safety issues. In addition, the collection of clinical, biological and image-based data may be used for retrospective analyses.